zadnja posodobitev :
19/11/2024
Infostab
Seznami
Seznami
Poiščite združljivosti
Tabela združljivosti Y-strani
Viri
raziskovalne skupine
valistab
poster
Povezave
sponzorji
Avtor
Navodilo za uporabo
Newsletter
Etoposide
Kemična formula
Lastniško ime
Sestava pomožnih snovi je med paralelami lahko različna
Eposin
Belgija, Južnoafriška republika, Kolumbija, Malezija, Norveška, Švedska, Velika Britanija
Etocris
Argentina, Čile, Peru
Etolon
Indija
Etomedac
Luksemburg, Nemčija
Etonolver
Venezuela
Etoposide
Francija, Grčija, Nizozemska
Etosid
Egipt, Indija, Malezija
Eunades
Brazilija
Euvaxon
Argentina
Exitop
Finska, Nemčija, Švedska
Fytosid
Egipt, Indija, Malezija
Lastet
Egipt, Iran, Italija, Madžarska, Poljska, Turčija, Združeni arabski emirati
Onkoposid
Nemčija
Riboposid
Nemčija
Sedol
Peru
Toposin
Nizozemska
Tosuben
Mehika
Vepesid
Avstralija, Avstrija, Belgija, Danska, Egipt, Finska, Grčija, Hrvaška, Irska, Italija, Južnoafriška republika, Kanada, Kolumbija, Luksemburg, Madžarska, Nemčija, Nizozemska, Poljska, Savdska Arabija, Slovenija, Španija, Švica, Turčija, Združene države Amerike
Vepeside
Maroko, Tunizija
Viri : Etoposide
Tip
objava
3
časopis
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57
časopis
Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81
časopis
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84
časopis
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85
časopis
Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91
časopis
Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99
časopis
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
140
časopis
Pearson SD, Trissel LA.
Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components.
Am J Hosp Pharm 1993 ; 50: 1405-1409.
150
časopis
Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
152
časopis
Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J.
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion.
Pharm Acta Helv 1995 ; 70: 141-148.
161
časopis
Barthes DM, Rochard EB, Pouliquen IJ, Rabouan SM, Courtois PY.
Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers.
Am J Hosp Pharm 1994 ; 51: 2706-2709.
169
časopis
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182
časopis
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
184
časopis
Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244
časopis
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249
časopis
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251
časopis
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307
časopis
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
331
časopis
Marquardt ED.
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Am J Hosp Pharm 1988 ; 45: 2127.
334
časopis
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335
časopis
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
417
časopis
Stewart CF, Hampton EM.
Stability of cisplatin and etoposide in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 1400-1404.
482
časopis
Beijnen JH, Beijnen-Bandhoe U, Dubbelman AC, Van Gijn R, Underberg WJM.
Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.
J Parenter Sci Technol 1991 ; 45: 108-112.
491
časopis
Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492
časopis
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
504
časopis
Hamon M, Plas-Remoissenet D, Kubab-Alajati S.
Etude de la stabilité dans des solutions diluées destinées à la perfusion de deux antimitotiques dérivés de la podophyllotoxine : l’étoposide (VP 16), le téniposide (VM 26).
Sci Tech Pharm 1987 ; 3: 33-40.
643
časopis
Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR.
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide.
Cancer Treat Rep 1987 ; 71: 1189-1192.
905
časopis
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1026
časopis
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033
časopis
Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 1999 ; 56: 985-989.
1423
časopis
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496
časopis
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520
Traduction Laboratorij
Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1613
časopis
Lepage R, Walker SE, Godin J.
Stability and compatibility of etoposide in normal saline.
Can J Hosp Pharm 2000 ; 53: 338-345.
1722
časopis
Gras C, Sautou-Miranda V, Bagel-Boithias S, Brigas F, Chopineau J.
Compatibility of etoposide solution with polyvinyl chloride and low density polyethylene containers and its stability in different storage conditions.
EJHP 2002 ; 2: 33-40.
1730
časopis
Björkman S, Roth B.
Chemical compatibility of mitoxantrone and etoposide (VP-16).
Act Pharm Nord 1991 ; 3: 251.
1819
časopis
Demoré B, Vigneron J, Perrin A, Hoffman MA, Hoffman M.
Leaching of diethyl hexyl phtalate from polyvinyl chloride bags into intravenous etoposide solution.
J Clin Pharm Ther 2002 ; 27: 139-142.
1895
časopis
Bourdeaux D, Sautou-Miranda V, Bagel-Boithias S, Boyer A, Chopineau J.
Analysis by liquid chromatography and infrared spectrometry of di(2-ethylhexyl)phtalate released by multilayer infusion tubing.
J Pharm Biomed Anal 2004 ; 35: 57-64.
1984
časopis
Bagel-Boithias S, Sautou-Miranda V, Bourdeaux D, Tramier V, Boyer A, Chopineau J.
Leaching of diethylhexyl phtalate from multilayer tubing into etoposide infusion solutions.
Am J Health-Syst Pharm 2005 ; 62: 182-188.
2108
časopis
Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2167
časopis
Joel SP, Clark PI, Slevin ML.
Stability of the iv and oral formulations of etoposide in solution.
Cancer Chemother Pharmacol 1995 ; 37, 1: 117-124.
3574
Traduction Laboratorij
Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3670
časopis
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
4024
poster
Sadou Yaye H, Rieber Z, HassaniI L, Hoffmann-Martinot C, Babiard M, Aouti H, Bellanger A, Tilleul P.
Pénurie mondiale d'Etopophos et conséquences pratiques : Intérêt des études de stabilité dans le choix d'un générique.
SFPO Congress 2017 - Nantes 2017
4125
časopis
D'Huart E, Vigneron J, Lider P, Demoré B.
Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags.
EJHP 2020 ; 27, 1: 43-48.
4304
časopis
Klasen K, Kessari R, Mercier L, Valade C, Grill J, Desmaris R, Paci A.
Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices.
Drugs R D 2014 ; 14:13?23.
4352
časopis
Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y.
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
J Clin Pharm Ther 2019 ; 44: 875-882.
4369
časopis
Sadou Yayé H, Hassani L, Secrétan PH, Babiard M, Aouati H, Bellanger A, Tilleul P, Yagoubi N, Do B, Rietveld I.
Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate
J Pharm Biomed Anal 2020 ;178:112896
Mentions Légales